SOAT1 and glioblastoma: AG490 is a JAK2 inhibitor that has demonstrated efficacy in mitigating STAT3 activity through downregulation of STAT-regulated genes MMP2 and MMP9 in GBM cell lines, albeit exhibiting limited anticancer effect in vivo [62, 65, 81, 82].